Bio-Rad Laboratories, Inc. (BIO) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics.
Is Bio-Rad Laboratories, Inc. stock overvalued or undervalued in 2026?
Bio-Rad Laboratories, Inc. (BIO) trades at 45.1× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $251 (-33 %).
Kaplio overview: Bio-Rad Laboratories, Inc.
Market cap $10B · 52 weeks $242 – $390 (5 % below the high) · P/E 45.1× · 2027 est. P/E 36.3× · Dividend none · Next earnings November 4, 2026 · expected EPS $2.23 · Closing price, Oct 30 · accounts published Aug 4.
- Valuation: P/E 45.1× (expensive).
- Business: ROIC 2 % (weak).
- Balance sheet: Net debt/EBITDA 0.8× (solid).
- Earnings: 5 of 8 (uneven).
What would it be worth at its usual multiples?
At its sector median (30.4×) $251 (-33 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 2 of 7 pass
- R&D / Revenue 9.9 %, fails.
- 5y EPS growth −26.3 %, fails.
- Gross margin 52.0 %, fails.
- FCF / Net Income 49.3 %, fails.
- ROIC 1.5 %, fails.
- Net debt / EBITDA 0.8×, passes.
- P/E vs own 10y history 45.1×, passes.
Against its peers (reference peers) — Bio-Rad Laboratories, Inc.: P/E 45.1×; EV/EBITDA 20.7×; ROIC 1.5 %; $10.0B. Bruker Corporation (P/E —; EV/EBITDA 42.1×; ROIC 2.6 %; $8.7B), Repligen Corporation (P/E —; EV/EBITDA 89.0×; ROIC -1.0 %; $11.2B), Bio-Techne Corporation (P/E 62.6×; EV/EBITDA 33.3×; ROIC 7.8 %; $11.4B).
Profitability
| Return on Equity | 3.15% |
| Return on Invested Capital | 1.54% |
| Return on Assets | 2.17% |
| Gross Margin | 51.90% |
| Operating Margin | 9.08% |
| Net Margin | 8.59% |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 3.14 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 3.27 |
Price Performance
| 1 month | +0.82% |
| 3 months | +11.19% |
| Year-to-date | +22.84% |
| 1 year | +16.47% |
| 3 years | +32.36% |
| 5 years | -52.23% |
| 10 years | +126.21% |
Related companies: TECH · RGEN · BRKR · MRVI · TMO · DHR · RVTY
Explore sector: Healthcare · Medical - Devices
More sections of BIO: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks